Reversing cancer multidrug resistance: Insights into the efflux by ABC transports from in silico studies

Wiley Interdisciplinary Reviews: Computational Molecular Science

Volumn 5, Issue 1, 2015, Pages 27-55

  Ferreira, Ricardo J ^a   Ferreira, Maria José U ^a   dos Santos, Daniel J V A ^a,b  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

COORDINATION REACTIONS; GLYCOPROTEINS;

COMPLEX ARCHITECTURES; COMPLEX PROCESSES; COMPUTATIONAL STUDIES; COMPUTATIONAL TECHNIQUE; CONFORMATIONAL CHANGE; EXPERIMENTAL EVIDENCE; MOLECULAR ASPECTS; MULTIDRUG RESISTANCE;

DISEASES;

EID: 84919463679     PISSN: 17590876     EISSN: 17590884     Source Type: Journal    
DOI: 10.1002/wcms.1196     Document Type: Review

References (206)

1. Jordan K, Proskorovsky I, Lewis P, Ishak J, Payne K, Lordan N, Kyriakou C, Williams CD, Peters S, Davies FE. Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study. Support Care Cancer 2013, 22:417-426.
2. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
3. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v3.0, cancer incidence and mortality worldwide: IARC CancerBase No. 10, Lyon, France; 2010. Available at: http://globocan.iarc.fr. (Accessed April 24, 2014).
4. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002, 53:615-627.
5. Cutts JH, Beer CT, Noble RL. Biological properties of Vincaleukoblastine, an alkaloid in Vinca Rosea Linn, with reference to its antitumor action. Cancer Res 1960, 20:1023-1031.
6. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971, 93:2325-2327.
7. Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer 1967, 20:333-353.
8. Zahreddine H, Borden KLB. Mechanisms and insights into drug resistance in cancer. Front Pharmacol 2013, 4:28.
9. Baguley BC. Multiple drug resistance mechanisms in cancer. Mol Biotechnol 2010, 46:308-316.
10. Gillet J-P, Gottesman MM. Mechanisms of multidrug resistance in cancer. Methods Mol Biol 2010, 596:47-76.
11. Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009, 9:665-674.
12. Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer 2012, 12:133-143.
13. Callaghan R, George AM, Kerr ID. Molecular aspects of the translocation process by ABC proteins. Comp Biophys 2012, 8:145-173.
14. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976, 455:152-162.
15. Eckford PDW, Sharom FJ. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 2009, 109:2989-3011.
16. Yamagishi T, Sahni S, Sharp DM, Arvind A, Jansson PJ, Richardson DR. P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration. J Biol Chem 2013, 288:31761-31771.
17. Ford RC, Kamis AB, Kerr ID, Callaghan R. The ABC transporters: structural insights into drug transport. In: Ecker G, Chiba P, eds. Transporters as Drug Carriers. Methods and Principles in Medicinal Chemistry, vol. 44. Weinheim: Wiley-VCH; 2009, 3-48.
18. Dawson RJP, Locher KP. Structure of a bacterial multidrug ABC transporter. Nature 2006, 443:180-185.
19. Sharom FJ, Liu R, Qu Q, Romsicki Y. Exploring the structure and function of the P-glycoprotein multidrug transporter using fluorescence spectroscopic tools. Semin Cell Dev Biol 2001, 12:257-265.
20. Rosenberg MF, Callaghan R, Modok S, Higgins CF, Ford RC. Three-dimensional structure of P-glycoprotein: the transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state. J Biol Chem 2005, 280:2857-2862.
21. Locher KP. Structure and mechanism of ATP-binding cassette transporters. Philos Trans R Soc Lond B 2009, 364:239-245.
22. Sharom FJ, Lugo MR, Eckford PDW. New insights into the drug binding, transport and lipid flippase activities of the P-glycoprotein multidrug transporter. J Bioenerg Biomembr 2005, 37:481-487.
23. Vanakker OM, Hosen MJ, Paepe AD. The ABCC6 transporter: what lessons can be learnt from other ATP-binding cassette transporters? Front Genet 2013, 4:203.
24. Borges-Walmsley MI, McKeegan KS, Walmsley AR. Structure and function of efflux pumps that confer resistance to drugs. Biochem J 2003, 376:313-338.
25. Sharom FJ. The P-glycoprotein multidrug transporter. Essays Biochem 2011, 50:161-178.
26. Van Assema DME, Lubberink M, Bauer M, van der Flier WM, Schuit RC, Windhorst AD, Comans EFI, Hoetjes NJ, Tolboom N, Langer O, et al. Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain 2012, 135:181-189.
27. Lam FC, Liu R, Lu P, Shapiro AB, Renoir JM, Sharom FJ, Reiner PB. β-Amyloid efflux mediated by P-glycoprotein. J Neurochem 2001, 76:1121-1128.
28. Kuhnke D, Jedlitschky G, Grube M, Krohn M, Jucker M, Mosyagin I, Cascorbi I, Walker LC, Kroemer HK, Warzok RW, et al. MDR1-P-glycoprotein (ABCB1) mediates transport of Alzheimer's amyloid-β peptides-implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol 2007, 17:347-353.
29. Orlowski S, Martin S, Escargueil A. P-glycoprotein and "lipid rafts": some ambiguous mutual relationships (floating on them, building them or meeting them by chance?). Cell Mol Life Sci 2006, 63:1038-1059.
30. Higgins CF, Gottesman MM. Is the multidrug transporter a flippase? Trends Biochem Sci 1992, 17:18-21.
31. Eckford PDW, Sharom FJ. The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids. Biochem J 2005, 389:517-526.
32. Shapiro AB, Fox K, Lam P, Ling V. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Eur J Biochem 2001, 259:841-850.
33. Kwon Y, Kamath AV, Morris ME. Inhibitors of P-glycoprotein-mediated daunomycin transport in rat liver canalicular membrane vesicles. J Pharm Sci 1996, 85:935-939.
34. Rosenberg MF, Mao Q, Holzenburg A, Ford RC, Deeley RG, Cole SP. The structure of the multidrug resistance protein 1 (MRP1/ABCC1). Crystallization and single-particle analysis. J Biol Chem 2001, 276:16076-16082.
35. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 1999, 59:8-13.
36. Mo W, Zhang J-T. Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol 2012, 3:1-27.
37. Jardetzky O. Simple allosteric model for membrane pumps. Nature 1966, 211:969-970.
38. Sharom FJ. The P-glycoprotein efflux pump: how does it transport drugs? J Membr Biol 1997, 160:161-175.
39. Callaghan R, Ford RC, Kerr ID. The translocation mechanism of P-glycoprotein. FEBS Lett 2006, 580:1056-1063.
40. Ambudkar SV, Kim I, Sauna ZE. The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharm Sci 2006, 27:392-400.
41. Altenberg GA, Vanoye CG, Horton JK, Reuss L, Julie K. Unidirectional fluxes of rhodamine 123 in multidrug-resistant cells: evidence against direct drug extrusion from the plasma membrane. Proc Natl Acad Sci U S A 1994, 91:4654-4657.
42. Homolya L, Holló Z, Germann UA, Pastan I, Gottesman MM, Sarkadi B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 1993, 268:21493-21496.
43. Romsicki Y, Sharom FJ. The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry 1999, 38:6887-6896.
44. Wang RB, Kuo CL, Lien LL, Lien EJ-C. Structure-activity relationship: analyses of P-glycoprotein substrates and inhibitors. J Clin Pharm Ther 2003, 28:203-228.
45. Lu P, Liu R, Sharom FJ. Drug transport by reconstituted P-glycoprotein in proteoliposomes. Effect of substrates and modulators, and dependence on bilayer phase state. Eur J Biochem 2001, 268:1687-1697.
46. Raviv Y, Pollard HB, Bruggemann EP, Pastan I, Gottesman MM. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J Biol Chem 1990, 265:3975-3980.
47. Senior AE, Al-Shawi MK, Urbatsch IL. The catalytic cycle of P-glycoprotein. FEBS Lett 1995, 377:285-289.
48. Urbatsch IL, Senior AE. Effects of lipids on ATPase activity of purified Chinese hamster P-glycoprotein. Arch Biochem Biophys 1995, 316:135-140.
49. Shapiro AB, Corder AB, Ling V. P-glycoprotein-mediated Hoechst 33342 transport out of the lipid bilayer. Eur J Biochem 1997, 250:115-121.
50. Shapiro AB, Ling V. Transport of LDS-751 from the cytoplasmic leaflet of the plasma membrane by the Rhodamine-123-selective site of P-glycoprotein. Eur J Biochem 1998, 254:181-188.
51. Shapiro AB, Ling V. Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem Pharmacol 1997, 53:587-596.
52. Parveen Z, Stockner T, Bentele C, Pferschy S, Kraupp M, Freissmuth M, Ecker GF, Chiba P. Molecular dissection of dual pseudosymmetric solute translocation pathways in human P-glycoprotein. Mol Pharmacol 2011, 79:443-452.
53. Shapiro AB, Ling V. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 1997, 250:130-137.
54. Tsuruo T, Lida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981, 141:1967-1972.
55. Tsuruo T, Iida H, Kitatani Y, Yokota K, Tsukagoshi S, Sakurai Y. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. Cancer Res 1984, 44:4303-4307.
56. Twentyman PR, Fox NE, White DJ. Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line. Br J Cancer 1987, 56:55-57.
57. Höllt V, Kouba M, Dietel M, Vogt G. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem Pharmacol 1992, 43:2601-2608.
58. Hofmann J, Gekeler V, Ise W, Noller A, Mitterdorfer J, Hofer S, Utz I, Gotwald M, Boer R, Glossmann H. Mechanism of action of dexniguldipine-HCl (B8509-035), a new potent modulator of multidrug resistance. Biochem Pharmacol 1995, 49:603-609.
59. Peck RA, Hewett J, Harding MW, Wang YM, Chaturvedi PR, Bhatnagar A, Ziessman H, Atkins F, Hawkins MJ. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J Clin Oncol 2001, 19:3130-3141.
60. Nüssler V, Pelka-Fleisc R, Gieseler F, Hasmann M, Löser R, Gullis E, Stötzer O, Zwierzina H, Wilmanns W. In vitro efficacy of known P-glycoprotein modulators compared to droloxifene E and Z: studies on a human T-cell leukemia cell line and their resistant variants. Leuk Lymphoma 1998, 31:589-597.
61. Palmeira A, Sousa E, Vasconcelos MH, Pinto M. Three decades of P-Gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem 2012, 19:1946-2025.
62. Martin C, Berridge G, Mistry P, Higgins CF, Charlton P, Callaghan R. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol 1999, 128:403-411.
63. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993, 53:4595-4602.
64. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Bumol TF, Starling JJ. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996, 56:4171-4179.
65. Van Zuylen L, Sparreboom A, van der Gaast A, van der Burg ME, van Beurden V, Bol CJ, Woestenborghs R, Palmer PA, Verweij J. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin Cancer Res 2000, 6:1365-1371.
66. Conseil G, Baubichon-Cortay H, Dayan G, Jault J-M, Barron D, Pietro AD, Di Pietro A. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proc Natl Acad Sci U S A 1998, 95:9831-9836.
67. Reis MA, Ferreira RJ, Santos MMM, dos Santos DJVA, Molnár J, Ferreira M-JU. Enhancing macrocyclic diterpenes as multidrug-resistance reversers: structure-activity studies on Jolkinol D derivatives. J Med Chem 2013, 56:748-760.
68. Ramalhete C, Molnár J, Mulhovo S, Rosário VE, Ferreira M-JU. New potent P-glycoprotein modulators with the cucurbitane scaffold and their synergistic interaction with doxorubicin on resistant cancer cells. Bioorg Med Chem 2009, 17:6942-6951.
69. Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, Polli JW. In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 2006, 34:786-792.
70. Hendrich A, Michalak K. Lipids as a target for drugs modulating multidrug resistance of cancer cells. Pharm Res 2003, 4:23-30.
71. Palmeira A, Sousa E, Vasconcelos H, Pinto M, Fernandes MX. Structure and ligand-based design of P-glycoprotein inhibitors: a historical perspective. Curr Pharm Des 2012, 18:4197-4224.
72. Liu H, Ma Z, Wu B. Structure-activity relationships and in silico models of P-glycoprotein (ABCB1) inhibitors. Xenobiotica 2013, 43:1018-1026.
73. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009, 323:1718-1722.
74. Ward AB, Szewczyk P, Grimard V, Lee C-W, Martinez L, Doshi R, Caya A, Villaluz M, Pardon E, Cregger C, et al. Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain. Proc Natl Acad Sci U S A 2013, 110:13386-13391.
75. Seelig A. How does P-glycoprotein recognize its substrates? Int J Clin Pharmacol Ther 1998, 36:50-54.
76. Pearce HL, Safa AR, Bach NJ, Winter MA, Cirtain MC, Beck WT. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc Natl Acad Sci U S A 1989, 86:5128-5132.
77. Suzuki T, Fukazawa N, San-nohe K. Structure-activity relationship of newly synthesized quinoline derivatives for reversal of multidrug resistance in cancer. J Med Chem 1997, 40:2047-2052.
78. Hait WN, Aftab DT. Rational design and pre-clinical pharmacology of drugs for reversing multidrug resistance. Biochem Pharmacol 1992, 43:103-107.
79. Schwaha R, Ecker GF. Use of shape similarities for the classification of P-glycoprotein substrates and nonsubstrates. Future Med Chem 2011, 3:1117-1128.
80. Wang Z, Chen Y, Liang H, Bender A, Glen RC, Yan A. P-glycoprotein substrate models using support vector machines based on a comprehensive data set. J Chem Inf Model 2011, 51:1447-1456.
81. Didziapetris R, Japertas P, Avdeef A, Petrauskas A. Classification analysis of P-glycoprotein substrate specificity. J Drug Target 2003, 11:391-406.
82. Broccatelli F. QSAR models for P-glycoprotein transport based on a highly consistent data set. J Chem Inf Model 2012, 52:2462-2470.
83. Desai PV, Sawada GA, Watson IA, Raub TJ. Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux. Mol Pharm 2013, 10:1249-1261.
84. Desai PV, Raub TJ, Blanco M-J. How hydrogen bonds impact P-glycoprotein transport and permeability. Bioorg Med Chem Lett 2012, 22:6540-6548.
85. Levatić J, Curak J, Kralj M, Smuc T, Osmak M, Supek F. Accurate models for P-Gp drug recognition induced from a cancer cell line cytotoxicity screen. J Med Chem 2013, 56:5691-5708.
86. Broccatelli F, Carosati E, Neri A, Frosini M, Goracci L, Oprea TI, Cruciani G. A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. J Med Chem 2011, 54:1740-1751.
87. Ferreira RJ, dos Santos DJVA, Ferreira M-JU, Guedes RC. Toward a better pharmacophore description of P-glycoprotein modulators, based on macrocyclic diterpenes from euphorbia species. J Chem Inf Model 2011, 51:1315-1324.
88. Leong MK, Chen H-B, Shih Y-H. Prediction of promiscuous P-glycoprotein inhibition using a novel machine learning scheme. PLoS One 2012, 7:e33829.
89. Wiese M, Pajeva IK. Structure-activity relationships of multidrug resistance reversers. Curr Med Chem 2001, 8:685-713.
90. Klepsch F, Vasanthanathan P, Ecker GF. Ligand and structure-based classification models for prediction of P-glycoprotein inhibitors. J Chem Inf Model 2014, 54:218-229.
91. Tan W, Mei H, Chao L, Liu T, Pan X, Shu M, Yang L. Combined QSAR and molecule docking studies on predicting P-glycoprotein inhibitors. J Comput Aided Mol Des 2013, 27:1067-1073.
92. Sousa IJ, Ferreira M-JU, Molnár J, Fernandes MX. QSAR studies of macrocyclic diterpenes with P-glycoprotein inhibitory activity. Eur J Org Chem 2012, 48:542-553.
93. Madhavan T, Gadhe CG, Kothandan G, Cho SJ. Enhancement of P-gylcoprotein modulators of arylmethylamine-phenyl derivatives: an integrative modeling approach. Med Chem Res 2012, 22:2511-2523.
94. Jabeen I, Wetwitayaklung P, Chiba P, Pastor M, Ecker GF. 2D- and 3D-QSAR studies of a series of benzopyranes and benzopyrano[3, 4b][1, 4]-oxazines as inhibitors of the multidrug transporter P-glycoprotein. J Comput Aided Mol Des 2013, 27:161-171.
95. Brincat JP, Broccatelli F, Sabatini S, Frosini M, Neri A, Kaatz GW, Cruciani G, Carosati E. Ligand promiscuity between the efflux pumps human P-glycoprotein and S. aureus NorA. ACS Med Chem Lett 2012, 3:248-251.
96. Zhu T, Chen J, Yang J. Some substrates of P-glycoprotein targeting β-amyloid clearance by quantitative structure-activity relationship (QSAR)/membrane-interaction (MI)-QSAR analysis. Adv Biosci Biotechnol 2013, 4:872-895.
97. Lagunin AA, Gloriozova TA, Dmitriev AV, Volgina NE, Poroikov VV. Computer evaluation of drug interactions with P-glycoprotein. Bull Exp Biol Med 2013, 154:521-524.
98. Poongavanam V, Haider N, Ecker GF. Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. Bioorg Med Chem 2012, 20:5388-5395.
99. Rapposelli S, Coi A, Imbriani M, Bianucci AM. Development of classification models for identifying "true" P-glycoprotein (P-Gp) inhibitors through inhibition, ATPase activation and monolayer efflux assays. Int J Mol Sci 2012, 13:6924-6943.
100. Verma J, Khedkar VM, Coutinho EC. 3D-QSAR in drug design-a review. Curr Top Med Chem 2010, 10:95-115.
101. Clay AT, Sharom FJ. Lipid bilayer properties control membrane partitioning, binding, and transport of P-glycoprotein substrates. Biochemistry 2013, 52:343-354.
102. Kuntz ID, Chen K, Sharp KA, Kollman PA. The maximal affinity of ligands. Proc Natl Acad Sci U S A 1999, 96:9997-10002.
103. Chang G. RETRACTED: structure of MsbA from vibrio cholera: a multidrug resistance ABC transporter homolog in a closed conformation. J Mol Biol 2003, 330:419-430.
104. Chang G, Roth CB. Structure of MsbA from E. coli: a homolog of the multidrug resistance ATP binding cassette (ABC) transporters. Science 2001, 293:1793-1800.
105. Chang G. Retraction of "Structure of MsbA from vibrio cholera: a multidrug resistance ABC transporter homolog in a closed conformation" [J. Mol. Biol. (2003)330 419-430]. J Mol Biol 2007, 369:596.
106. Chang G, Roth CB, Reyes CL, Pornillos O, Chen Y-J, Chen AP. Retraction of "Structure Pf MsbA from E. coli: a homolog of the multidrug resistance ATP binding cassette (ABC) transporter" [Science (2001) 293 1793-1800]. Science 2006, 314:1875.
107. Locher KP, Lee AT, Rees DC. The E. coli BtuCD structure: a framework for ABC transporter architecture and mechanism. Science 2002, 296:1091-1098.
108. Dawson RJP, Locher KP. Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP-PNP. FEBS Lett 2007, 581:935-938.
109. Ward A, Reyes CL, Yu J, Roth CB, Chang G. Flexibility in the ABC transporter MsbA: alternating access with a twist. Proc Natl Acad Sci U S A 2007, 104:19005-19010.
110. Jin MS, Oldham ML, Zhang Q, Chen J. Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans. Nature 2012, 490:566-569.
111. Loo TW, Clarke DM. Drug rescue distinguishes between different structural models of human P-glycoprotein. Biochemistry 2013, 52:7167-7169.
112. Shintre CA, Pike ACW, Li Q, Kim J-I, Barr AJ, Goubin S, Shrestha L, Yang J, Berridge G, Ross J, et al. Structures of ABCB10, a human ATP-binding cassette transporter in Apo- and nucleotide-bound states. Proc Natl Acad Sci U S A 2013, 110:9710-9715.
113. Chen L, Morrow JK, Tran HT, Phatak SS, Du-Cuny L, Zhang S. From laptop to benchtop to bedside: structure-based drug design on protein targets. Curr Pharm Des 2012, 18:1217-1239.
114. Anderson AC. The process of structure-based drug design. Chem Biol 2003, 10:787-797.
115. Dolghih E, Bryant C, Renslo AR, Jacobson MP. Predicting binding to P-glycoprotein by flexible receptor docking. PLoS Comput Biol 2011, 7:e1002083.
116. Loo TW, Bartlett MC, Clarke DM. Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein. J Biol Chem 2003, 278:39706-39710.
117. Klepsch F, Chiba P, Ecker GF. Exhaustive sampling of docking poses reveals binding hypotheses for propafenone type inhibitors of P-glycoprotein. PLoS Comput Biol 2011, 7:e1002036.
118. Jabeen I, Wetwitayaklung P, Klepsch F, Parveen Z, Chiba P, Ecker GF. Probing the stereoselectivity of P-glycoprotein-synthesis, biological activity and ligand docking studies of a set of enantiopure benzopyrano[3, 4-b][1, 4]oxazines. Chem Commun 2011, 47:2586-2588.
119. Jabeen I, Pleban K, Rinner U, Chiba P, Ecker GF. Structure-activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone-type inhibitors of the multidrug transporter P-glycoprotein. J Med Chem 2012, 55:3261-3273.
120. Palmeira A, Vasconcelos MH, Paiva A, Fernandes MX, Pinto M, Sousa E. Dual Inhibitors of P-glycoprotein and tumor cell growth: (re)discovering thioxanthones. Biochem Pharmacol 2012, 83:57-68.
121. Schwede T. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res 2003, 31:3381-3385.
122. Singh DV, Godbole MM, Misra K. A plausible explanation for enhanced bioavailability of P-Gp substrates in presence of piperine: simulation for next generation of P-Gp inhibitors. J Mol Model 2013, 19:227-238.
123. Pajeva IK, Sterz K, Christlieb M, Steggemann K, Marighetti F, Wiese M. Interactions of the multidrug resistance modulators tariquidar and elacridar and their analogues with P-glycoprotein. ChemMedChem 2013, 8:1701-1713.
124. Pajeva IK, Hanl M, Wiese M. Protein contacts and ligand binding in the inward-facing model of human P-glycoprotein. ChemMedChem 2013, 8:748-762.
125. Pajeva I, Wiese M. Application of in silico methods to study ABC transporters involved in multidrug resistance. In: Miteva MA, ed. In-Silico Lead Discovery. Paris: Bentham Science Publishers Ltd; 2011, 144-162.
126. Ferreira RJ, Ferreira M-JU, dos Santos DJVA. Molecular docking characterizes substrate-binding sites and efflux modulation mechanisms within P-glycoprotein. J Chem Inf Model 2013, 53:1747-1760.
127. Jara GE, Vera DMA, Pierini AB. Binding of modulators to mouse and human multidrug resistance P-glycoprotein. A computational study. J Mol Graph Model 2013, 46:10-21.
128. Wise JG. Catalytic transitions in the human MDR1 P-glycoprotein drug binding sites. Biochemistry 2012, 51:5125-5141.
129. Loo TW, Clarke DM. Identification of residues within the drug-binding domain of the human multidrug resistance P-glycoprotein by cysteine-scanning mutagenesis and reaction with dibromobimane. J Biol Chem 2000, 275:39272-39278.
130. Loo TW, Clarke DM. Identification of residues in the drug-binding domain of human P-glycoprotein. Analysis of transmembrane segment 11 by cysteine-scanning mutagenesis and inhibition by dibromobimane. J Biol Chem 1999, 274:35388-35392.
131. Loo TW, Clarke DM. Defining the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil, MTS-Verapamil. J Biol Chem 2001, 276:14972-14979.
132. Shityakov S, Förster C. Multidrug resistance protein P-Gp interaction with nanoparticles fullerenes and carbon nanotube) to assess their drug delivery potential: a theoretical molecular docking study. Int J Comput Biol Drug Des 2013, 6:343-357.
133. Xu X, Li R, Ma M, Wang X, Wang Y, Zou H. Multidrug resistance protein P-glycoprotein does not recognize nanoparticle C60: experiment and modeling. Soft Matter 2012, 8:2915-2923.
134. Prajapati R, Singh U, Patil A, Khomane KS, Bagul P, Bansal AK, Sangamwar AT. In silico model for P-glycoprotein substrate prediction: insights from molecular dynamics and in vitro studies. J Comput Aided Mol Des 2013, 27:347-363.
135. Cleave SSA, Panda R, Suresh PK. In silico exploration of phenytoin binding site in two catalytic states of human P-glycoprotein models. Indian J Biochem Biophys 2013, 50:7-13.
136. Yamaguchi H, Kidachi Y, Kamiie K, Noshita T, Umetsu H. Homology modeling and structural analysis of human P-glycoprotein. Bioinformation 2012, 8:1066-1074.
137. Yang C, Zhang T, Li Z, Xu L, Liu F, Ruan J, Liu K, Zhang Z. P-glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies. Toxicol Appl Pharmacol 2013, 273:561-568.
138. Tajima Y, Nakagawa H, Tamura A, Kadioglu O, Satake K, Mitani Y, Murase H, Regasini LO, da Silva Bolzani V, Ishikawa T, et al. Nitensidine A, a guanidine alkaloid from Pterogyne nitens, is a novel substrate for human ABC transporter ABCB1. Phytomedicine 2014, 21:323-332.
139. ®), a BRAF inhibitor, modulates ABCB1-, ABCG2-, and ABCC10-mediated multidrug resistance. J Can Res Update 2013, 2:306-317.
140. Martinez L, Arnaud O, Henin E, Tao H, Chaptal V, Doshi R, Andrieu T, Dussurgey S, Tod M, Di Pietro A, et al. Understanding polyspecificity within the substrate-binding cavity of the human multidrug resistance P-glycoprotein. FEBS J 2014, 281:673-682.
141. Singh S, Prasad NR, Kapoor K, Chufan EE, Patel BA, Ambudkar SV, Talele TT. Design, synthesis, and biological evaluation of (S)-valine thiazole-derived cyclic and noncyclic peptidomimetic oligomers as modulators of human P-glycoprotein (ABCB1). ChemBioChem 2014, 15:157-169.
142. Li X, Hu J, Wang B, Sheng L, Liu Z, Yang S, Li Y. Inhibitory effects of herbal constituents on P-glycoprotein in vitro and in vivo: herb-drug interactions mediated via P-Gp. Toxicol Appl Pharmacol 2013, 275:163-175.
143. Vilas-Boas V, Silva R, Palmeira A, Sousa E, Ferreira LM, Branco PS, Carvalho F, Bastos M d L, Remião F. Development of novel rifampicin-derived P-glycoprotein activators/inducers. Synthesis, in silico analysis and application in the RBE4 cell model, using paraquat as substrate. PLoS One 2013, 8:e74425.
144. Marcoux J, Wang SC, Politis A, Reading E, Ma J, Biggin PC, Zhou M, Tao H, Zhang Q, Chang G, et al. Mass spectrometry reveals synergistic effects of nucleotides, lipids, and drugs binding to a multidrug resistance efflux pump. Proc Natl Acad Sci U S A 2013, 110:9704-9709.
145. Lucas X, Simon S, Schubert R, Günther S. Discovery of the inhibitory effect of a phosphatidylinositol derivative on p-glycoprotein by virtual screening followed by in vitro cellular studies. PLoS One 2013, 8:e60679.
146. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009, 30:2785-2791.
147. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, Banks JL. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 2004, 47:1750-1759.
148. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010, 31:455-461.
149. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD. Improved protein-ligand docking using GOLD. Proteins 2003, 52:609-623.
150. Hrycyna CA, Airan LE, Germann UA, Ambudkar SV, Pastan I, Gottesman MM. Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport. Biochemistry 1998, 37:13660-13673.
151. Sato T, Kodan A, Kimura Y, Ueda K, Nakatsu T, Kato H. Functional role of the linker region in purified human P-glycoprotein. FEBS J 2009, 276:3504-3516.
152. Caffrey M. Membrane protein crystallization. J Struct Biol 2003, 142:108-132.
153. Lacapère J-J, Pebay-Peyroula E, Neumann J-M, Etchebest C. Determining membrane protein structures: still a challenge!. Trends Biochem Sci 2007, 32:259-270.
154. Lee AG. Lipid-protein interactions in biological membranes: a structural perspective. Biochim Biophys Acta 2003, 1612:1-40.
155. Klappe K, Hummel I, Hoekstra D, Kok JW. Lipid dependence of ABC transporter localization and function. Chem Phys Lipids 2009, 161:57-64.
156. Ivetac A, Sansom MSP. Molecular dynamics simulations and membrane protein structure quality. Eur Biophys J 2008, 37:403-409.
157. Aänismaa P, Gatlik-Landwojtowicz E, Seelig A. P-glycoprotein senses its substrates and the lateral membrane packing density: consequences for the catalytic cycle. Biochemistry 2008, 47:10197-10207.
158. Gunaydin H, Weiss MM, Sun YD. Novo prediction of P-glycoprotein-mediated efflux liability for druglike compounds. ACS Med Chem Lett 2013, 4:108-112.
159. Ma J, Biggin PC. Substrate versus inhibitor dynamics of P-glycoprotein. Proteins 2013, 81:1653-1668.
160. Oliveira AS, Baptista AM, Soares CM. Conformational changes induced by ATP-hydrolysis in an ABC transporter: a molecular dynamics study of the Sav1866 exporter. Proteins 2011, 79:1977-1990.
161. Moradi M, Tajkhorshid E. Mechanistic picture for conformational transition of a membrane transporter at atomic resolution. Proc Natl Acad Sci U S A 2013, 110:18916-18921.
162. Loo TW. The packing of the transmembrane segments of human multidrug resistance P-glycoprotein is revealed by disulfide cross-linking analysis. J Biol Chem 2000, 275:5253-5256.
163. Urbatsch IL, Gimi K, Wilke-Mounts S, Lerner-Marmarosh N, Rousseau ME, Gros P, Senior AE. Cysteines 431 and 1074 are responsible for inhibitory disulfide cross-linking between the two nucleotide-binding sites in human P-glycoprotein. J Biol Chem 2001, 276:26980-26987.
164. Yuan YR, Blecker S, Martsinkevich O, Millen L, Thomas PJ, Hunt JF. The crystal structure of the MJ0796 ATP-binding cassette. Implications for the structural consequences of ATP hydrolysis in the active site of an ABC transporter. J Biol Chem 2001, 276:32313-32321.
165. Smith PC, Karpowich N, Millen L, Moody JE, Rosen J, Thomas PJ, Hunt JF. ATP binding to the motor domain from an ABC transporter drives formation of a nucleotide sandwich dimer. Mol Cell 2002, 10:139-149.
166. Zaitseva J, Oswald C, Jumpertz T, Jenewein S, Wiedenmann A, Holland IB, Schmitt L. A structural analysis of asymmetry required for catalytic activity of an ABC-ATPase domain dimer. EMBO J 2006, 25:3432-3443.
167. Furukawa-Hagiya T, Furuta T, Chiba S, Sohma Y, Sakurai M. The power stroke driven by ATP binding in CFTR as studied by molecular dynamics simulations. J Chem Phys B 2013, 117:83-93.
168. Higgins CF, Linton KJ. The ATP switch model for ABC transporters. Nat Struct Mol Biol 2004, 11:918-926.
169. Jones PM, George AM. Opening of the ADP-bound active site in the ABC transporter ATPase dimer: evidence for a constant contact, alternating sites model for the catalytic cycle. Proteins 2009, 75:387-396.
170. Oliveira ASF, Baptista AM, Soares CM. Insights into the molecular mechanism of an abc transporter: conformational changes in the NBD dimer of MJ0796. J Phys Chem B 2010, 114:5486-5496.
171. Damas JM, Oliveira ASF, Baptista AM, Soares CM. Structural consequences of ATP hydrolysis on the ABC transporter NBD dimer: molecular dynamics studies of HlyB. Protein Sci 2011, 20:1220-1230.
172. George AM, Jones PM. An asymmetric post-hydrolysis state of the ABC transporter ATPase dimer. PLoS One 2013, 8:e59854.
173. Becker J-P, Van Bambeke F, Tulkens PM, Prévost M. Dynamics and structural changes induced by ATP binding in SAV1866, a bacterial ABC exporter. J Phys Chem B 2010, 114:15948-15957.
174. Jones PM, George AM. Molecular-dynamics simulations of the ATP/apo state of a multidrug ATP-binding cassette transporter provide a structural and mechanistic basis for the asymmetric occluded state. Biophys J 2011, 100:3025-3034.
175. Aittoniemi J, de Wet H, Ashcroft FM, Sansom MSP. Asymmetric switching in a homodimeric ABC transporter: a simulation study. PLoS Comput Biol 2010, 6:e1000762.
176. Oloo EO, Tieleman DP. Conformational transitions induced by the binding of MgATP to the vitamin B12 ATP-binding cassette (ABC) transporter BtuCD. J Biol Chem 2004, 279:45013-45019.
177. Garrigues A, Escargueil AE, Orlowski S. The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc Natl Acad Sci U S A 2002, 99:10347-10352.
178. Loo TW, Clarke DM. The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface. J Biol Chem 1999, 274:24759-24765.
179. Rosenberg MF, Velarde G, Ford RC, Martin C, Berridge G, Kerr ID, Callaghan R, Schmidlin A, Wooding C, Linton KJ, et al. Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle. EMBO J 2001, 20:5615-5625.
180. Kleywegt GJ. Validation of protein crystal structures. Acta Crystallogr D Biol Crystallogr 2000, 56:249-265.
181. Biggin PC, Bond PJ. Molecular dynamics simulations of membrane proteins. Methods Mol Biol 2008, 443:147-160.
182. Fan H, Mark AE. Relative stability of protein structures determined by X-ray crystallography or NMR spectroscopy: a molecular dynamics simulation study. Proteins 2003, 53:111-120.
183. Brunger AT, Adams PD. Refinement of X-ray crystal structures. In: Egelman EH, ed. Comprehensive Biophysics. Elsevier Inc; 2012, 105-115.
184. Burnley BT, Afonine PV, Adams PD, Gros P. Modelling dynamics in protein crystal structures by ensemble refinement. Elife 2012, 1:e00311.
185. O'Mara ML, Tieleman DP. P-glycoprotein models of the Apo and ATP-bound states based on homology with Sav1866 and MalK. FEBS Lett 2007, 581:4217-4222.
186. Chang S-Y, Liu F-F, Dong X-Y, Sun Y. Molecular insight into conformational transmission of human P-glycoprotein. J Chem Phys 2013, 139:225102.
187. Wen P-C, Verhalen B, Wilkens S, Mchaourab HS, Tajkhorshid E. On the origin of large flexibility of P-glycoprotein in the inward-facing state. J Biol Chem 2013, 288:19211-19220.
188. O'Mara ML, Mark AE. The effect of environment on the structure of a membrane protein: P-glycoprotein under physiological conditions. J Chem Theory Comput 2012, 8:3964-3976.
189. Ferreira RJ, Ferreira M-JU, dos Santos DJVA. Insights on P-glycoprotein's efflux mechanism obtained by molecular dynamics simulations. J Chem Theory Comput 2012, 8:1853-1864.
190. Ferreira RJ, Ferreira M-JU, dos Santos DJVA. Assessing the stabilization of P-glycoprotein's nucleotide-binding domains by the linker, using molecular dynamics. Mol Inf 2013, 32:529-540.
191. Zhang J, Sun T, Liang L, Wu T, Wang Q. Drug promiscuity of P-glycoprotein and its mechanism of interaction with paclitaxel and doxorubicin. Soft Matter 2014, 10:438.
192. Watanabe Y, Hsu W-L, Chiba S, Hayashi T, Furuta T, Sakurai M. Dynamics and structural changes induced by ATP and/or substrate binding in the inward-facing conformation state of P-glycoprotein. Chem Phys Lett 2013, 557:145-149.
193. Liu M, Hou T, Feng Z, Li Y. The flexibility of P-glycoprotein for its poly-specific drug binding from molecular dynamics simulations. J Biomol Struct Dyn 2013, 31:612-629.
194. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 1998, 251:252-261.
195. Dolghih E, Jacobson MP. Predicting efflux ratios and blood-brain barrier penetration from chemical structure: combining passive permeability with active efflux by P-glycoprotein. ACS Chem Neurosci 2013, 4:361-367.
196. Reis M, Ferreira RJ, Serly J, Duarte N, Madureira AM, dos Santos DJVA, Molnár J, Ferreira M-JU. Colon adenocarcinoma multidrug resistance reverted by euphorbia diterpenes: structure-activity relationships and pharmacophore modeling. Anticancer Agents Med Chem 2012, 12:1015-1024.
197. Nagar S, Tucker J, Weiskircher EA, Bhoopathy S, Hidalgo IJ, Korzekwa K. Compartmental models for apical efflux by P-glycoprotein-part 1: evaluation of model complexity. Pharm Res 2014, 31:347-359.
198. Korzekwa K, Nagar S. Compartmental models for apical efflux by P-glycoprotein: part 2-a theoretical study on transporter kinetic parameters. Pharm Res 2013, 31:335-346.
199. Neuhoff S, Yeo KR, Barter Z, Jamei M, Turner DB, Rostami-Hodjegan A. Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux. J Pharm Sci 2013, 102:3145-3160.
200. Neuhoff S, Yeo KR, Barter Z, Jamei M, Turner DB, Rostami-Hodjegan A. Application of permeability-limited physiologically-based pharmacokinetic models: part II-prediction of P-glycoprotein mediated drug-drug interactions with digoxin. J Pharm Sci 2013, 102:3161-3173.
201. Alonso H, Bliznyuk AA, Gready JE. Combining docking and molecular dynamic simulations in drug design. Med Res Rev 2006, 26:531-568.
202. Beveridge DL, DiCapua FM. Free energy via molecular simulation: applications to chemical and biomolecular systems. Ann Rev Biophys Biophys Chem 1989, 18:431-492.
203. Cramer CJ. Essentials of Computational Chemistry: Theories and Models. 2nd ed. John Wiley and Sons Ltd; 2004, 1-618.
204. Klopman G, Shi LM, Ramu A. Quantitative structure-activity relationship of multidrug resistance reversal agents. Mol Pharmacol 1997, 52:323-334.
205. Lindahl ER. Molecular dynamics simulations. In: Kukol A, ed. Methods in Molecular Biology, Humana Press; 2008, 443: 3-23.
206. Szakács G, Homolya L, Sarkadi B, Váradi A. MDR-ABC transporters. In: Offermanns S, Rosenthal W, eds. Encyclopedia of Molecular Pharmacology. Berlin, Heidelberg: Springer; 2008, 748-752.